Ivonescimab
PulseAugur coverage of Ivonescimab — every cluster mentioning Ivonescimab across labs, papers, and developer communities, ranked by signal.
- 2026-08-27 research_milestone Akeso's Ivonescimab demonstrated superior performance compared to AstraZeneca's Imfinzi in a Phase 3 trial for biliary tract cancer. source
1 day(s) with sentiment data
-
Global interest in Chinese biotech surges with major pharma deals
Global interest in Chinese biotech is rising, evidenced by significant deals involving major pharmaceutical companies. AstraZeneca is investing $2 billion in Summit Therapeutics, which is advancing Akeso's immunotherapy…
-
Akeso's Ivonescimab Outperforms AstraZeneca's Imfinzi in Cancer Trial
Chinese biopharmaceutical company Akeso announced that its immunotherapy drug, Ivonescimab, outperformed AstraZeneca's Imfinzi in a Phase 3 trial for biliary tract cancer. This trial, involving 682 patients, is the firs…
-
Akeso's lung cancer drug shows 34% reduced death risk in trials
Akeso's lung cancer drug, ivonescimab, has shown significant promise in phase three clinical trials, reducing the risk of death by 34%. The drug demonstrated a notable survival benefit, with 64.7% of patients alive afte…